KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Asset Writedowns and Impairment: 2022-2025

Historic Asset Writedowns and Impairment for Charles River Laboratories International (CRL) over the last 3 years, with Sep 2025 value amounting to $5.0 million.

  • Charles River Laboratories International's Asset Writedowns and Impairment rose 61.28% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.2 million, marking a year-over-year increase of 91.19%. This contributed to the annual value of $51.8 million for FY2024, which is 23.65% up from last year.
  • According to the latest figures from Q3 2025, Charles River Laboratories International's Asset Writedowns and Impairment is $5.0 million, which was down 75.85% from $20.6 million recorded in Q2 2025.
  • In the past 5 years, Charles River Laboratories International's Asset Writedowns and Impairment registered a high of $27.0 million during Q4 2024, and its lowest value of -$7,000 during Q3 2023.
  • Over the past 3 years, Charles River Laboratories International's median Asset Writedowns and Impairment value was $10.5 million (recorded in 2023), while the average stood at $11.1 million.
  • Within the past 5 years, the most significant YoY rise in Charles River Laboratories International's Asset Writedowns and Impairment was 126,071.43% (2024), while the steepest drop was 80.39% (2024).
  • Over the past 4 years, Charles River Laboratories International's Asset Writedowns and Impairment (Quarterly) stood at $6.7 million in 2022, then surged by 134.25% to $15.7 million in 2023, then spiked by 71.88% to $27.0 million in 2024, then soared by 61.28% to $5.0 million in 2025.
  • Its last three reported values are $5.0 million in Q3 2025, $20.6 million for Q2 2025, and $10.6 million during Q1 2025.